女性膀胱癌盆腔器官保留机器人辅助根治性膀胱切除术
这项回顾性多中心队列研究纳入269例接受机器人辅助根治性膀胱切除术(RARC)的女性膀胱癌患者,其中81例接受盆腔器官保留RARC。两组肿瘤学结局与并发症发生率相似,高分级并发症在器官保留组与非器官保留组分别为早期13% vs 14%(P=0.87)、晚期7% vs 6%(P=0.70)。作者认为对经过良好选择的女性膀胱癌患者可考虑盆腔器官保留RARC。
要点
- 269例女性膀胱癌患者接受RARC,其中81例接受盆腔器官保留RARC。
- 两组肿瘤学结局相似,复发率、癌症特异性生存(CSS)和总生存(OS)均无显著差异。
- 高分级并发症相似:器官保留组 vs 非器官保留组早期13% vs 14%(P=0.87),晚期7% vs 6%(P=0.70)。
核心结论
- 接受盆腔器官保留RARC及体内尿流改道的女性膀胱癌患者,其肿瘤学结局与并发症结局与非器官保留RARC者相似。
- 作者认为,对经过良好选择的女性膀胱癌患者可考虑盆腔器官保留RARC,以改善生活质量和功能结局。
研究设计与样本
- 回顾性多中心队列研究,纳入接受RARC及体内尿流改道的女性膀胱癌患者269例,其中81例接受盆腔器官保留RARC。
- 主要结局为总生存(OS)和癌症特异性生存(CSS),次要结局为30天和90天高分级并发症。
- 采用Kaplan-Meier分析、log-rank检验和Cox比例风险模型评估盆腔器官保留RARC与OS及CSS的关联。
主要发现
- 两组临床或病理T分期无统计学显著差异,两组复发率相似。
- 两组CSS或OS无显著差异。
- 两组并发症谱和发生率相似。
- 高分级(Clavien-Dindo分级≥3a)并发症发生率两组相似:器官保留组 vs 非器官保留组早期为13% vs 14%(P=0.87),晚期为7% vs 6%(P=0.70)。
临床怎么用
- 作者认为,对经过良好选择的女性膀胱癌患者可考虑盆腔器官保留RARC,以改善生活质量和功能结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the oncological and complication outcomes in women who have undergone pelvic organ-sparing robot-assisted radical cystectomy (RARC). PATIENTS AND METHODS: We conducted a retrospective, multicentre cohort study of women with bladder cancer undergoing RARC with intracorporeal urinary diversion. The primary outcomes were overall survival (OS) and cancer-specific survival (CSS), and secondary outcomes were 30- and 90-day high-grade complications in patients undergoing organ-sparing RARC vs non-organ-sparing RARC. Kaplan-Meier analyses, the log-rank test and Cox proportional hazard models were used to assess the associations of pelvic organ-sparing RARC with both OS and CSS. The Mann-Whitney test and chi-squared and Fisher's tests were used to compare continuous and categorical variables, respectively. RESULTS: A total of 269 women underwent RARC, of whom 81 underwent pelvic organ-sparing RARC. There was no statistically significant difference between the groups in terms of clinical or pathological T stage, and the recurrence rates were similar in the two groups. There were no significant differences in CSS or OS between the groups. The two groups had similar complication profiles and rates. The incidence of high-grade (Clavien-Dindo grade ≥3a) complications was similar in the two groups: organ-sparing vs non-organ-sparing RARC: 13% vs 14% for early complications (P = 0.87) and 7% vs 6% (P = 0.70) for late complications. CONCLUSIONS: Women with bladder cancer who underwent pelvic organ-sparing RARC and intracorporeal urinary diversion had similar oncological and complication outcomes compared to those who underwent non-organ-sparing RARC. Pelvic organ-sparing RARC could be considered in well selected women with bladder cancer, resulting in improved quality of life and functional outcomes.
引用
- Rautiola J, Björklund J, Ben-David R, et al. Pelvic organ-sparing robot-assisted radical cystectomy in women with bladder cancer. BJU Int. 2025. PMID: 40038779. doi:10.1111/bju.16691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。